Savara Inc (NASDAQ:SVRA) Holdings Raised by Connor Clark & Lunn Investment Management Ltd.

Connor Clark & Lunn Investment Management Ltd. boosted its holdings in Savara Inc (NASDAQ:SVRA) by 21.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 837,467 shares of the company’s stock after purchasing an additional 146,858 shares during the quarter. Connor Clark & Lunn Investment Management Ltd. owned approximately 0.49% of Savara worth $2,571,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of SVRA. Raymond James Financial Inc. bought a new position in shares of Savara during the fourth quarter valued at approximately $798,000. Charles Schwab Investment Management Inc. increased its position in Savara by 5.7% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 963,821 shares of the company’s stock worth $2,959,000 after buying an additional 52,204 shares during the period. Bank of New York Mellon Corp lifted its stake in Savara by 7.6% in the fourth quarter. Bank of New York Mellon Corp now owns 253,630 shares of the company’s stock valued at $779,000 after buying an additional 17,870 shares during the last quarter. Rhumbline Advisers boosted its holdings in shares of Savara by 6.8% during the fourth quarter. Rhumbline Advisers now owns 141,425 shares of the company’s stock valued at $434,000 after acquiring an additional 9,041 shares during the period. Finally, China Universal Asset Management Co. Ltd. grew its position in shares of Savara by 14.9% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 36,390 shares of the company’s stock worth $112,000 after acquiring an additional 4,732 shares during the last quarter. 87.93% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. Wells Fargo & Company started coverage on Savara in a report on Friday, December 20th. They set an “overweight” rating and a $8.00 price target on the stock. JMP Securities reaffirmed a “market outperform” rating and set a $9.00 target price on shares of Savara in a research note on Thursday, December 19th. One analyst has rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, Savara has a consensus rating of “Moderate Buy” and a consensus target price of $8.83.

Savara Trading Up 7.7 %

Shares of Savara stock opened at $2.81 on Tuesday. The business has a fifty day simple moving average of $2.74 and a 200-day simple moving average of $3.35. Savara Inc has a fifty-two week low of $2.26 and a fifty-two week high of $5.34. The firm has a market cap of $482.25 million, a price-to-earnings ratio of -6.53 and a beta of 0.60. The company has a quick ratio of 17.70, a current ratio of 17.70 and a debt-to-equity ratio of 0.13.

Savara Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.